Epizyme stock: buy or sell?

EPZM stock price: $18.22 19.08% At close on December 6th, 2019

Updated on:
December 6th, 2019

1

Epizyme shares rocketed 19.08% to $18.22 on December/6.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States.

Should I buy Epizyme stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading strategy that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Check the only buy setup that matches with Epizyme stock now:

Buy setupElegible
New all-time highNo
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Epizyme stock a buy?

Financial institutions and banks publish stock ratings everyday. At Stocks2.com, we gathered 5 ratings published for EPZM stock in the last 30 days.

The general sentiment of these ratings is bullish for EPZM stock, with 5 positive ratings.
Is EPZM a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-6-24HC Wainwrightn/aBuy
2019-6-12Wedbushn/aOutperform
2019-5-30Citigroupn/aBuy
2019-2-27Oppenheimern/aOutperform
2019-2-26Cowenn/aBuy

Epizyme stock analysis

Daily outlook

Shares of Epizyme closed on December 6th at $18.22 and rocketed an amazing 19.08%.

Epizyme rocketed an amazing 19.08% and closed at $18.22. Since last November 4th when EPZM stock price broke up the SMA200d line, it gained $6.37 (53.76%). EPZM shows a sign of strength in the short-term after finally breaking out above $17.00 on Nov/25 and marking a new rising bottom.

EPZM stock chart (daily)

Weekly outlook

Epizyme shares rocketed 10.29% this week, ending at $18.22. Counting this, it's been 5 climbing weeks in a row, soaring a 60.09%.

This week, SMA20w and SMA40w crossed up triggering a rise of 10.29%. Since early November when EPZM stock price broke up the SMA40w line, it gained $6.37 (53.76%).

EPZM stock chart (weekly)

Epizyme stock price history

Epizyme IPO was on May 31st, 2013 at $20.00 per share1. Since then, EPZM stock sliced a -8.90%, with a yearly average of -1.50%.

1: Adjusted price after possible price splits or reverse-splits.

Epizyme stock historical price chart

EPZM stock reached 52-week highs on December/6 at $18.39, and all-time highs 2013-07-17 with a price of 45.72.

Epizyme stock price target is $20.50

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we found 4 price forecasts for EPZM stock:
EPZM stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-24HC WainwrightSet Price Targetn/a$25.00-
2019-6-12WedbushReiteratesn/a$21.00-
2019-2-27OppenheimerLowers Target$27.00$18.00-33.3%
2019-2-26CowenReiteratesn/a$18.00-
(in average)$27.00$20.50-24.0%
The price target for Epizyme stock is $20.50, moving in a range between $25.00 and $18.00. In average, analysts' outlook on EPZM price target is negative, reducing the forecast by a -24.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Epizyme failed experts on February when it published an Earnings per Share (EPS) of $-0.29 when the analysts' forecast was $-0.49.
EPZM earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.56n/a
2017-Q2-n/a-0.48n/a
2017-Q32017-11-01-0.65-0.63n/a
2017-Q42018-03-13-0.56-0.52n/a
2018-Q12018-05-08-0.54-0.49n/a
2018-Q22018-08-02-0.53-0.42n/a
2018-Q32018-11-02-0.6-0.54n/a
2018-Q42019-02-26-0.49-0.29n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Epizyme annual sales rocketed an extraordinary 117.00% to $21.70 M USD from $10.00 marked in 2017. In line, its income margin (compared to revenues) boosted to -569.72%, that is $-123.63 million.

EPZM annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$68 M-$-3.48 M-5.1%-
2014$41 M-39.53%$-55.01 M-132.8%1,480.60%
2015$2.56 M-93.82%$-132.38 M-5170.9%140.66%
2016$8.01 M212.77%$-110.21 M-1376.4%-16.74%
2017$10 M24.89%$-134.31 M-1343.1%21.86%
2018$22 M117.00%$-123.63 M-569.7%-7.95%

Quarterly financial results

Epizyme reported $9.70 million in sales for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter earnings marked $-22.95 M with a profit margin of -236.55%. Profit margin remained steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Epizyme sales marked an exceptional increase and climbed a inf%.
EPZM quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$10 M-$-28.02 M-280.2%-
2018-Q2$12 M20.00%$-29.13 M-242.7%3.95%
2018-Q4$10 M-19.17%$-22.95 M-236.5%-21.23%

Epizyme ownership

When you are planning to invest in shares of a company, it's always worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Epizyme, 4.94% of all outstanding shares are owned by its staff.

Bearish positions for EPZM stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Epizyme:

EPZMABTDAREGSKNVS
Market cap$1.7 B$151.3 B$15.9 M$113.3 B$210.8 B
Total shares91.1 M1,770.0 M19.7 M2,490.0 M2,290.0 M
Float shares76.0 M1,760.0 M14.4 M2,450.0 M2,130.0 M
  - Institutional holdings (%)93.2%76.5%8.1%11.0%11.7%
  - Insider holdings (%)4.9%0.7%16.9%0.0%0.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Epizyme summary

Friday, December 6th, 2019
Open$16.41
Close$18.22
Day range$16.31 - $18.39
Previous close$15.30
Session gain19.08%
Average true range$0.83
50d mov avg$12.99
100d mov avg$12.76
200d mov avg$12.78
Daily patternlb02c
Weekly pattern lb06c

Epizyme performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Epizyme, the comparison is made against , Dare Bioscience, GlaxoSmithKline, Novartis and Seattle Genetics.
Stock3m6m12m
EPZMEpizyme39.72%28.13%182.48%
ABT-0.26%6.69%24.23%
DAREDare Bioscience1.25%-6.90%-5.81%
GSKGlaxoSmithKline9.32%16.96%28.23%
NVSNovartis2.63%4.55%21.82%
SGENSeattle Genetics66.76%66.55%95.87%

Epizyme competitors

One check before trading any stock is to review a list of its competitors, in this case for Epizyme. We chose 5 companies as Epizyme competitors as they are in the same industry or have similar market objectives.